Gilead will face pressure as too many retailers on board# Stock
f*y
1 楼
Every one is hyping the HCV sales this year, good projections everywhere...
f*y
2 楼
Idenix fell 4%, extending its pullback falling a big move upward in the week
before the Christmas holiday. The pre-holiday gains had resulted from hopes
that the company could win compensation in a patent dispute with Gilead
Sciences (NASDAQ: GILD ) concerning its Sovaldi hepatitis-C treatment. But
the pullback suggests that investors are far from certain about a positive
result from patent litigation, and with extensive doubts about its own
pipeline, Idenix needs to get some good news if it wants to secure longer-
lasting gains.
before the Christmas holiday. The pre-holiday gains had resulted from hopes
that the company could win compensation in a patent dispute with Gilead
Sciences (NASDAQ: GILD ) concerning its Sovaldi hepatitis-C treatment. But
the pullback suggests that investors are far from certain about a positive
result from patent litigation, and with extensive doubts about its own
pipeline, Idenix needs to get some good news if it wants to secure longer-
lasting gains.
相关阅读